Eupraxia Pharmaceuticals Inc.

TSX:EPRX Stock Report

Market Cap: CA$188.9m

Eupraxia Pharmaceuticals Management

Management criteria checks 1/4

Eupraxia Pharmaceuticals' CEO is James Helliwell, appointed in Jul 2012, has a tenure of 12.83 years. total yearly compensation is $1.38M, comprised of 28.5% salary and 71.5% bonuses, including company stock and options. directly owns 1.88% of the company’s shares, worth CA$3.55M. The average tenure of the management team and the board of directors is 2.5 years and 2.6 years respectively.

Key information

James Helliwell

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage28.49%
CEO tenure12.8yrs
CEO ownership1.9%
Management average tenure2.5yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

We're Keeping An Eye On Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Rate

Mar 22
We're Keeping An Eye On Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Rate

Health Check: How Prudently Does Eupraxia Pharmaceuticals (TSE:EPRX) Use Debt?

Jul 30
Health Check: How Prudently Does Eupraxia Pharmaceuticals (TSE:EPRX) Use Debt?

CEO Compensation Analysis

How has James Helliwell's remuneration changed compared to Eupraxia Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$27m

Dec 31 2024US$1mUS$394k

-US$26m

Sep 30 2024n/an/a

-US$28m

Jun 30 2024n/an/a

-US$27m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$517kUS$363k

-US$28m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$24m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$953kUS$325k

-US$18m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$1mUS$297k

-US$19m

Compensation vs Market: James's total compensation ($USD1.38M) is above average for companies of similar size in the Canadian market ($USD169.21K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.

CEO

James Helliwell (50 yo)

12.8yrs
Tenure
US$1,383,502
Compensation

Dr. James A. Helliwell, M.D., FRCPC serves as the Chief Executive Officer since July 2012 at Eupraxia Pharmaceuticals Inc. and served as its President until May 3, 2021. Dr. Helliwell serves as a Clinical...

Leadership Team

NamePositionTenureCompensationOwnership
James Helliwell
CEO & Director12.8yrsUS$1.38m1.88%
CA$ 3.6m
Amanda Malone
Chief Scientific Officer & COO12.7yrsUS$776.95k0.13%
CA$ 244.2k
Paul Brennan
Chief Business Officer2.5yrsUS$445.82k0.076%
CA$ 143.3k
Mark Kowalski
Chief Medical Officer2yrsUS$718.01k0.022%
CA$ 42.2k
Alexander Rothwell
Chief Financial Officerless than a yearUS$2.04m1.91%
CA$ 3.6m
2.5yrs
Average Tenure
52.5yo
Average Age

Experienced Management: EPRX's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Helliwell
CEO & Director12.8yrsUS$1.38m1.88%
CA$ 3.6m
Simon Pimstone
Independent Chairman12.3yrsUS$127.25k0.024%
CA$ 45.5k
Richard Glickman
Independent Director4.2yrsUS$115.06k0.039%
CA$ 73.4k
Paul Geyer
Independent Director12.3yrsUS$108.85k0.95%
CA$ 1.8m
Joseph Freedman
Independent Directorless than a yearUS$193.91k4.19%
CA$ 7.9m
John Montalbano
Independent Director12.3yrsUS$115.06k3.38%
CA$ 6.4m
Michael Wilmink
Independent Director12.3yrsUS$108.85k0.63%
CA$ 1.2m
Evan Dellon
Chairman of Clinical Advisory Board1yrno datano data
Donna Griebel
Member of Clinical Advisory Board1yrno datano data
Albert Bredenoord
Member of Clinical Advisory Board1yrno datano data
Roos Pouw
Member of Clinical Advisory Board1yrno datano data
Stephen Attwood
Member of Clinical Advisory Board1yrno datano data
2.6yrs
Average Tenure
57.5yo
Average Age

Experienced Board: EPRX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 23:08
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eupraxia Pharmaceuticals Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tania Armstrong-WhitworthCanaccord Genuity
Gum-Ming LoweCraig-Hallum Capital Group LLC
Gary NachmanRaymond James & Associates